title: Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck.
abstract: BACKGROUND
  In the current study, the authors assessed the efficacy of elective radiotherapy in providing regional (lymph node) control in patients with cutaneous melanoma of the head and neck who were at high risk for lymph node involvement. Toxicity was also assessed.
  
  
  METHODS
  From 1983 to 1998, 157 patients with Stage I or II cutaneous melanoma of the head and neck received elective regional radiotherapy after wide local excision of the primary lesion. None of the patients had received sentinel lymph node biopsy or dissection of the lymph nodes. Their medical records were reviewed retrospectively and analyzed for outcome.
  
  
  RESULTS
  The median follow-up for the current review was 68 months (range, 7-185 months). The disease recurred locally in 9 patients, in the neck lymph nodes in 15 patients, and distantly in 57 patients. The actuarial regional control rate was 89% at both 5 years and 10 years. The actuarial disease-specific survival and distant metastasis-free survival rates were 68% and 63%, respectively, at 5 years and 58% and 49%, respectively, at 10 years. Breslow thickness was a significant determinant of disease-specific survival and distant metastasis-free survival rates. At 10 years, 6% of patients had developed a symptomatic treatment-related complication. There were no treatment-related deaths.
  
  
  CONCLUSIONS
  The results of the current study confirmed the efficacy and safety of elective regional radiotherapy for patients with cutaneous head and neck melanoma predicted to have a high rate of lymph node involvement. Elective irradiation was a viable alternative to elective lymph node dissection. It may also serve as an alternative to sentinel lymph node biopsy, particularly for patients for whom dissection and systemic therapy are not therapeutic options.
authors.affiliation: Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Bonnen
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Ballo
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Myers
authors.forename: Adam S
authors.initials: AS
authors.lastname: Garden
authors.forename: Eduardo M
authors.initials: EM
authors.lastname: Diaz
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Gershenwald
authors.forename: William H
authors.initials: WH
authors.lastname: Morrison
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Lee
authors.forename: Mary Jane
authors.initials: MJ
authors.lastname: Oswald
authors.forename: Merrick I
authors.initials: MI
authors.lastname: Ross
authors.forename: K Kian
authors.initials: KK
authors.lastname: Ang
mesh_terms: D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D015182:Lymphatic Irradiation / Q000009:adverse effects; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D012189:Retrospective Studies; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000532:radiotherapy*; D016019:Survival Analysis